ArticleFrontiers in immunology2025
Durable complete response to PD-1 inhibitor in vesical calculus-associated squamous cell carcinoma: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder squamous cell carcinoma (SCC) is a rare histological subtype of bladder cancer (1%-5% of cases), with radical cystectomy as the primary recommended treatment. However, evidence for neoadjuvant/adjuvant chemotherapy or immunotherapy remains limited, especially for calculus-associated SCC. Case presentation: A 45-year-old male with vesical calculus-associated bladder SCC refused surgery and radiotherapy, and discontinued gemcitabine-cisplatin chemotherapy due to severe toxicity. He received tislelizumab (programmed death-1/PD-1 inhibitor, 200 mg q3w) and achieved a complete response (CR) after 8 cycles. Suprapubic cystolithotomy was safely performed during immunotherapy, and no tumor recurrence was observed for >24 months. Throughout the entire immunotherapy course, no severe immune-related adverse events occurred. Conclusion: Tislelizumab monotherapy may be a viable option for surgery-ineligible or chemotherapy-intolerant calculus-associated bladder SCC. Definitive stone removal under immunological tumor control is feasible, supporting further exploration of PD-1 inhibitors in this rare subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.